El-Mahallawy Hadir A, Shaker Heba H, Ali Helmy Hala, Mostafa Tarek, Razak Abo-Sedah Abdel
Department of Clinical Pathology, National Cancer Institute, Cairo, Eygpt.
Med Mycol. 2006 Dec;44(8):733-9. doi: 10.1080/13693780600939955.
Profound and prolonged neutropenia following chemotherapy is a major risk factor for systemic fungal infection. As the early diagnosis of invasive fungal infection (IFI) is difficult, these infections are still associated with high morbidity and mortality. Recently, Pan-fungal polymerase chain reaction (PCR) has been a promising aid in rapid, early diagnosis of IFI. During the past few years, increasing numbers of suspected IFIs were encountered at our institution in patients with prolonged neutropenia after intensified immunosuppressive chemotherapy. The aim of this study was to investigate the diagnostic utility of both the aspergillus galactomannan (GM) antigen and the pan-fungal PCR assay in the diagnosis of IFI in high risk febrile neutropenic paediatric cancer patients. During one year period, 91 febrile neutropenic (FN) paediatric cases at high risk for developing IFI while receiving chemotherapy were investigated at National Cancer Institute, Egypt. These patients were subjected to clinical evaluation, chest CT scan, conventional blood cultures for bacterial and fungal pathogens, aspergillus GM antigen detection and PCR assay utilizing pan-fungal primers. Of the 91 FN episodes, 15 were proven IFI; whereas 27 cases were either probable (n=13) or possible IFI (n=14), and 49 were unlikely to be IFI episodes. Based on positive results for proven/probable IFI and compared to culture results, Pan-fungal PCR showed sensitivity, specificity, positive and negative predictive values of 75%, 92%, 84% and 87%; respectively. Aspergillus antigen test showed a sensitivity of 79%, specificity of 61%, positive and negative predictive values of 54% and 83%; respectively. A negative PCR in the proven and probable cases was closely related to previous antifungal therapy for a prior history of IFI. In patients at high risk for IFI, neither the sensitivity, nor specificity of the GM test was sufficient. The results of PCR assay was reasonably specific but not very sensitive and had a chance of missing the diagnosis of IFI. The PCR assay seems a promising test for objectively defining IFI, but is not recommended as the only tool for diagnosing IFI. Combining microscopy, culture, and PCR may improve the diagnostic outcome.
化疗后出现的严重且持久的中性粒细胞减少是全身性真菌感染的主要危险因素。由于侵袭性真菌感染(IFI)的早期诊断困难,这些感染仍具有较高的发病率和死亡率。近年来,泛真菌聚合酶链反应(PCR)在IFI的快速、早期诊断方面显示出了良好的前景。在过去几年中,我院遇到越来越多在强化免疫抑制化疗后出现长期中性粒细胞减少的患者疑似患有IFI。本研究的目的是探讨曲霉半乳甘露聚糖(GM)抗原和泛真菌PCR检测在高危发热性中性粒细胞减少儿科癌症患者IFI诊断中的应用价值。在埃及国家癌症研究所,对91例在接受化疗期间有发生IFI高风险的发热性中性粒细胞减少(FN)儿科病例进行了为期一年的研究。这些患者接受了临床评估、胸部CT扫描、针对细菌和真菌病原体的传统血培养、曲霉GM抗原检测以及使用泛真菌引物的PCR检测。在91次FN发作中,15次被证实为IFI;27例为可能(n = 13)或疑似IFI(n = 14),49例不太可能是IFI发作。基于已证实/可能的IFI的阳性结果并与培养结果相比,泛真菌PCR的敏感性、特异性、阳性和阴性预测值分别为75%、92%、84%和87%;曲霉抗原检测的敏感性为79%,特异性为61%,阳性和阴性预测值分别为54%和83%。在已证实和可能的病例中,PCR阴性与先前因IFI病史而接受的抗真菌治疗密切相关。在IFI高危患者中,GM检测的敏感性和特异性均不足。PCR检测结果具有一定的特异性,但不太敏感,有可能漏诊IFI。PCR检测似乎是客观定义IFI的一项有前景的检测方法,但不建议作为诊断IFI的唯一工具。结合显微镜检查、培养和PCR可能会改善诊断结果。